en · de · es · fr · pt
selank-notes.peptides5388.com › Faq › Selank Handling, Stability, And Analysis — Background and Details

Selank Handling, Stability, And Analysis — Background and Details

By Editorial Desk · published 2025-08-15 · last reviewed 2025-09-26 · Faq

Tuftsin analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-09-26. Anything still debated is marked as such rather than presented as settled.

Selank Handling, Stability, and Analysis

Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.

Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.

Analytical Methods and Material Handling

Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.

Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.

Selank at a glance

PropertyValueNotes
Typical purity specification95 percent or higher by RP-HPLCArea percentage of the main peak
Identity confirmationElectrospray ionization mass spectrometryObserved mass compared with the theoretical value near 751.9 Da
Recommended dry storage-20 °C, desiccated-80 °C for multi-year archival material
Solution handlingPrepare fresh; avoid long storageSterile filtration reduces microbial load
Common synonymsTKPRPGP; TP-7Sequence code and laboratory designation used interchangeably

Administration, Testing and Availability

Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.

Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.

Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.

Related pages on this site

Storage, Analysis, and Regulatory Status

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.

Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.

Selank Background And Chemical Identity

Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.

Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.

Peptide Identity and Structure

The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.

Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.

Supporting material

== Further reading == Tucker H (2012). Blood Work: A Tale of Medicine and Murder in the Scientific Revolution. W. W. Norton & Company. ISBN 978-0-393-34223-9. "Milk as a Substitute for Blood Transfusion", historical account, Scientific American, 13 July 1878, p. 19

Congenital myopathy is a very broad term for any muscle disorder present at birth. This defect primarily affects skeletal muscle fibres and causes muscular weakness and/or hypotonia. Congenital myopathies account for one of the top neuromuscular disorders in the world today, comprising approximately 6 in 100,000 live births every year. As a whole, congenital myopathies can be broadly classified as follows:

==== 1700–1799 ==== A249 Trunk Road (Brielle Way/Docks Entrance) Order 1993 (S.I. 1993/1700) Craigie College of Education (Closure) (Scotland) Order 1993 (S.I. 1993/1701) Supply of Razors and Razor Blades (Interim Provision) (Revocation) Order 1993 (S.I. 1993/1702) Merger Situation (Stora/Swedish Match/Gillette) (Interim Provision) (Revocation) Order 1993 (S.I. 1993/1703) Land Registration (Charities) Rules 1993 (S.I. 1993/1704) A65 Trunk Road (Gargrave Bypass) Order 1990 Amendment and New Trunk Road Order 1993 (S.I. 1993/1705) A65 Trunk Road (Horse Pasture Laithe to Heber Barn) (Detrunking) Order 1993 (S.I. 1993/1706) Removal and Disposal of Vehicles(Amendment) (No. 3) Regulations 1993 (S.I. 1993/1708) Inshore Fishing (Prohibition of Fishing for Cockles) (Scotland) Order 1993 (S.I. 1993/1709) Motor Vehicles (Designation of Approval Marks) (Amendment) Regulations 1993 (S.I. 1993/1710) Plant Breeders' Rights (Trees, Shrubs and Woody Climbers) (Variation) Scheme 1993 (S.I. 1993/1733) Beef Special Premium Regulations 1993 (S.I. 1993/1734) Reconstitution of the Upper Witham Internal Drainage Board Order 1993 (S.I. 1993/1738) Social Security (Introduction of Disability Living Allowance) (Amendment) (No.2) Regulations 1993 (S.I. 1993/1739) Kent and East Sussex (County Boundaries) Order 1993 (S.I. 1993/1742) Coal Industry (Restructuring Grants) Order 1993 (S.I. 1993/1745) Chemicals (Hazard Information and Packaging) Regulations 1993 (S.I. 1993/1746) A35 Trunk Road (Tolpuddle to Puddletown Bypass and Slip Roads) Order 1993 (S.I.

=== Secondary causes === There are causes for deficiency other than low dietary intake of vitamin A as retinol or carotenes. Adequate dietary protein and caloric energy are needed for a normal rate of synthesis of RBP, without which, retinol cannot be mobilized to leave the liver. Systemic infections can cause transient decreases in RBP synthesis even if protein-calorie malnutrition is absent. Chronic alcohol consumption reduces liver vitamin A storage. Non-alcoholic fatty liver disease (NAFLD), characterized by the accumulation of fat in the liver, is the hepatic manifestation of metabolic syndrome. Liver damage from NAFLD reduces liver storage capacity for retinol and reduces the ability to mobilize liver stores to maintain normal circulating concentration. Vitamin A appears to be involved in the pathogenesis of anemia by diverse biological mechanisms, such as the enhancement of growth and differentiation of erythrocyte progenitor cells, potentiation of immunity to infection, and mobilization of iron stores from tissues.

=== British motivations === Britain ended the uneasy truce created by the Treaty of Amiens when it had declared war on France in May 1803. The British were increasingly angered by Napoleon's reordering of the international system in Western Europe, especially in Switzerland, Germany, Italy and the Netherlands. Kagan argues that Britain was especially alarmed by Napoleon's assertion of control over Switzerland. The British felt insulted when Napoleon said they deserved no voice in European affairs (even though King George was an elector of the Holy Roman Empire) and sought to censor the London newspapers that were vilifying him. Britain had a sense of loss of control, as well as loss of markets, and was worried by Napoleon's possible threat to its overseas colonies. McLynn argues that Britain went to war in 1803 out of a "mixture of economic motives and national neuroses—an irrational anxiety about Napoleon's motives and intentions." McLynn concludes that it proved to be the right choice for Britain because, in the long run, Napoleon's intentions were hostile to the British national interest. Napoleon was not ready for war, and so this was the best time for Britain to stop them. Britain seized upon the Malta issue, refusing to evacuate the island. The deeper British grievance with Napoleon was his attempts to assume personal control of Europe, making the international system unstable, and forcing Britain to the sidelines. Numerous scholars have argued that Napoleon's aggressive posture made him enemies and cost him potential allies.

Sources: en.wikipedia.org

Supporting material

==== MeSH D06.472.040 – adrenal cortex hormones ==== MeSH D06.472.040.502 – 17-ketosteroids MeSH D06.472.040.502.112 – androstenedione MeSH D06.472.040.502.195 – androsterone MeSH D06.472.040.502.497 – estrone MeSH D06.472.040.502.583 – etiocholanolone MeSH D06.472.040.502.620 – dehydroepiandrosterone MeSH D06.472.040.502.620.300 – dehydroepiandrosterone sulfate MeSH D06.472.040.585 – hydroxycorticosteroids MeSH D06.472.040.585.353 – 11-hydroxycorticosteroids MeSH D06.472.040.585.353.118 – aldosterone MeSH D06.472.040.585.353.237 – corticosterone MeSH D06.472.040.585.353.476 – hydrocortisone MeSH D06.472.040.585.353.500 – 18-hydroxycorticosterone MeSH D06.472.040.585.353.825 – tetrahydrocortisol MeSH D06.472.040.585.478 – 17-hydroxycorticosteroids MeSH D06.472.040.585.478.195 – cortisone MeSH D06.472.040.585.478.225 – cortodoxone MeSH D06.472.040.585.478.392 – hydrocortisone MeSH D06.472.040.585.478.782 – tetrahydrocortisol MeSH D06.472.040.585.478.865 – tetrahydrocortisone MeSH D06.472.040.585.611 – desoxycorticosterone MeSH D06.472.040.585.611.400 – 18-hydroxydesoxycorticosterone MeSH D06.472.040.585.745 – pregnenolone MeSH D06.472.040.585.745.500 – 17-alpha-hydroxypregnenolone

Uniformity and precision in dosage for each dosage form. Results of therapeutic effects during the course of the treatment. Physical stability and appeal of the drug. Labeling of storage conditions and expiration dates.

Dysregulation of O-GlcNAc is associated with cancer cell proliferation and tumor growth. O-GlcNAcylation of the glycolytic enzyme PFK1 at S529 has been found to inhibit PFK1 enzymatic activity, reducing glycolytic flux and redirecting glucose towards the pentose phosphate pathway. Structural modeling and biochemical experiments suggested that O-GlcNAc at S529 would inhibit PFK1 allosteric activation by fructose 2,6-bisphosphate and oligomerization into active forms. In a mouse model, mice injected with cells expressing PFK1 S529A mutant showed lower tumor growth than mice injected with cells expressing PFK1 wild-type. Additionally, OGT overexpression enhanced tumor growth in the latter system but had no significant effect on the system with mutant PFK1. Hypoxia induces PFK1 S529 O-GlcNAc and increases flux through the pentose phosphate pathway to generate more NADPH, which maintains glutathione levels and detoxifies reactive oxygen species, imparting a growth advantage to cancer cells. PFK1 was found to be glycosylated in human breast and lung tumor tissues. OGT has also been reported to positively regulate HIF-1α. HIF-1α is normally degraded under normoxic conditions by prolyl hydroxylases that utilize α-ketoglutarate as a co-substrate. OGT suppresses α-ketoglutarate levels, protecting HIF-1α from proteasomal degradation by pVHL and promoting aerobic glycolysis.

== Activation == All MMPs are synthesized in the latent form (Zymogen). They are secreted as proenzymes and require extracellular activation. They can be activated in vitro by many mechanisms including organomercurials, chaotropic agents, and other proteases.

Sources: en.wikipedia.org

Supporting material

It has been found to interact with AGEs and participate in their clearance. This receptor is primarily expressed on endothelial cells and plays a role in maintaining vascular health by reducing the burden of AGE-modified proteins. SR-BII (Scavenger Receptor Class B Type II):SR-BII is similar to SR-BI but has distinct functions. It binds AGEs and has been implicated in mediating the uptake of modified proteins. SR-BII is involved in lipid transfer processes and, like SR-BI, may contribute to mitigating AGE-induced cellular stress. DC-SIGN (Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin): DC-SIGN is a receptor expressed on dendritic cells that plays a key role in pathogen recognition and immune response. Emerging research suggests that DC-SIGN can bind AGEs and mediate their clearance, reducing AGE-induced immune activation.

Morgan made a surprise appearance at the 67th Primetime Emmy Awards on September 20, 2015, and was greeted with a standing ovation. He also hosted the first Spike Guys' Choice Awards, which aired on June 13, 2007.

Biochemically, individuals with ALD show very high levels of unbranched, saturated, very long chain fatty acids, particularly cerotic acid (26:0). The level of cerotic acid in plasma does not correlate with clinical presentation. Treatment options for ALD are limited. For the childhood cerebral form, stem cell transplant and gene therapy are options if the disease is detected early in the clinical course. Adrenal insufficiency in ALD patients can be successfully treated. ALD is the most common peroxisomal inborn error of metabolism, with a minimum estimated incidence of 1:42,000 for hemizygotes and 1:16,800 for hemizygotes and heterozygotes, though the incidence is likely to increase with improved newborn screening. It does not have a significantly higher incidence in any specific ethnic group.

== Discovery == Factor XIII Deficiency is also known as Laki–Lorand factor, after Kalman Laki and Laszlo Lorand, the scientists who first proposed its existence in 1948. A 2005 conference recommended standardization of nomenclature.

=== Alcohol abuse === Before his marriage, Bush repeatedly abused alcohol. On September 4, 1976, he was pulled over near his family's summer home in Kennebunkport, Maine, for driving under the influence of alcohol. He was arrested for DUI, was fined $150, and received a brief suspension of his Maine driver's license. Bush said that his wife has had a stabilizing effect on his life, and he attributes his decision to give up alcohol in 1986 to her influence. While governor of Texas, Bush said of his wife, "I saw an elegant, beautiful woman who turned out not only to be elegant and beautiful, but very smart and willing to put up with my rough edges, and I must confess has smoothed them off over time." Bush also says that his faith in God was critical in abstaining: "I believe that God helped open my eyes, which were closing because of booze".

Sources: en.wikipedia.org

Frequently asked questions

How should selank powder be stored?

Sealed, desiccated storage at -20 °C or colder is the standard recommendation for research-grade material. Vials should reach room temperature before they are opened, which limits condensation. Repeated temperature cycling is discouraged.

Why does purity testing matter?

A reported purity value reflects the share of the main peak in one chromatographic run and says nothing about identity. Confirming that the expected sequence is present requires a separate measurement such as mass spectrometry. Purity and identity are distinct questions.

What does a mass spectrum show?

A mass spectrum reports the molecular masses present in a sample and shows whether they match the value expected for selank, near 751.9 Da. It also flags common artifacts such as truncation or adduct formation. It does not establish correct stereochemistry or complete sequence order on its own.

How is purity determined?

Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.

Network